News Related to Hemophilia B

Related coverage linked through entity extraction aliases.

European Commission expands Pfizer's Hympavzi approval for hemophilia patients with inhibitors

May 14, 2026

The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.

Pfizer Advances Oncology Pipeline with BRAFTOVI Trial Success and HYMPAVZI Expansion

Mar 06, 2026

Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.